mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC
Condition(s):Colorectal Cancer; ImmunotherapyLast Updated:July 13, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Colorectal Cancer; ImmunotherapyLast Updated:July 13, 2023Recruiting
Condition(s):Neurofibromatosis 2Last Updated:January 17, 2023Recruiting
Condition(s):Ovarian Cancer; Ovarian Carcinoma; Ovary Cancer; Fallopian Tube Cancer; Primary Peritoneal CarcinomaLast Updated:August 2, 2022Recruiting
Condition(s):Non-small Cell Lung Cancer Stage II; Bevacizumab; Immunotherapy; Brain MetastasesLast Updated:April 11, 2023Not yet recruiting
Condition(s):Colorectal CancerLast Updated:January 19, 2024Recruiting
Condition(s):Ovarian NeoplasmsLast Updated:July 1, 2022Not yet recruiting
Condition(s):Malignant Neoplasms of Female Genital Organs; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal CancerLast Updated:January 16, 2024Recruiting
Condition(s):Non-small Cell Lung CancerLast Updated:February 23, 2024Recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:November 10, 2021Recruiting
Condition(s):Hereditary Hemorrhagic TelangiectasiaLast Updated:May 1, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.